Mohammad Jahan Shams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Jahan Shams has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Sarwar Alam
Department of Clinical Oncology, Bangladesh Medical University, Dhaka, Bangladesh
8 shared publicationsMizanur Rahman
Department of Radiation Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh
6 shared publicationsZillur Rahman Bhuiyan
Department of Clinical Oncology, Bangladesh Medical University, Dhaka, Bangladesh
6 shared publicationsKaoser Alam
Department of Internal Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
4 shared publicationsSajib Kumar Talukdhar
4 shared publicationsShourov Biswas
Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD
4 shared publications
Latest Publications
- Open Access
- 7 March 2026
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Care
- Vol. 11 (2) , 219-224
Comparative Efficacy of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy versus Chemoradiotherapy Alone in Inoperable Locally Advanced Head and Neck Cancer: A Quasi-Experimental Study
Introduction: Head and neck cancer is a common oncological problem in Bangladesh. Most of the head and neck cancers present with a locally advanced stage. Concurrent chemoradiotherapy (CCRT) is the current standard for inoperable locally advanced head and neck cancer (LAHNC). Several studies explored the induction chemotherapy (ICT) option before CCRT and found promising outcomes. Objective: The study aimed at assessing the complete response rate and toxicity of CCRT with or without ICT in inoperable LAHNC. Materials and Methods: This quasi-experimental study enrolled 140 patients from June 2018 to July 2019. Participants were included based on the inclusion and exclusion criteria and equally divided between the two arms: 70 patients in Arm A (ICT plus CCRT) and 70 patients in Arm B (CCRT). ICT and CCRT were given to Arm A, while CCRT alone was given to Arm B. Three months following completion of the treatment, the final outcomes were assessed. Results: At the final follow-up, Arm A showed a statistically higher complete response rate compared to Arm B (58.57% versus 32.85%, p-value = 0.002). Treatment-related toxicities, such as mucositis, xerostomia, dermatitis, anemia, neutropenia and renal toxicity, were similar in both arms. Conclusion: Patients who received ICT before CCRT had a significantly higher complete response rate compared to those who received CCRT alone with comparable toxicities. Therefore, ICT may improve locoregional control when added before CCRT in inoperable LAHNC.
- 7 March 2026
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Care
- Vol. 11 (2) , 219-224
Open AccessComparative Efficacy of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy versus Chemoradiotherapy Alone in Inoperable Locally Advanced Head and Neck Cancer: A Quasi-Experimental Study
Introduction: Head and neck cancer is a common oncological problem in Bangladesh. Most of the head and neck cancers present with a locally advanced stage. Concurrent chemoradiotherapy (CCRT) is the current standard for inoperable locally advanced head and neck cancer (LAHNC). Several studies explored the induction chemotherapy (ICT) option before CCRT and found promising outcomes. Objective: The study aimed at assessing the complete response rate and toxicity of CCRT with or without ICT in inoperable LAHNC. Materials and Methods: This quasi-experimental study enrolled 140 patients from June 2018 to July 2019. Participants were included based on the inclusion and exclusion criteria and equally divided between the two arms: 70 patients in Arm A (ICT plus CCRT) and 70 patients in Arm B (CCRT). ICT and CCRT were given to Arm A, while CCRT alone was given to Arm B. Three months following completion of the treatment, the final outcomes were assessed. Results: At the final follow-up, Arm A showed a statistically higher complete response rate compared to Arm B (58.57% versus 32.85%, p-value = 0.002). Treatment-related toxicities, such as mucositis, xerostomia, dermatitis, anemia, neutropenia and renal toxicity, were similar in both arms. Conclusion: Patients who received ICT before CCRT had a significantly higher complete response rate compared to those who received CCRT alone with comparable toxicities. Therefore, ICT may improve locoregional control when added before CCRT in inoperable LAHNC.
- Open Access
- 25 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e79636
Weekly Versus Three-Weekly Administration of Paclitaxel as Neoadjuvant Chemotherapy in HER2 Negative, Stage III Breast Cancer: A Comparison of Treatment Responses
Background and aim: Neoadjuvant chemotherapy with doxorubicin (A) and cyclophosphamide (C) followed by taxane (T) (AC followed by T) is one of the standard regimens in locoregionally advanced breast cancer. Paclitaxel, a taxane, can be given either in a three-weekly or a weekly schedule. The aim of this study was to compare the efficacy in terms of the clinical and pathological response of three-weekly paclitaxel with weekly paclitaxel in the treatment of human epidermal growth factor receptor 2 (HER2)-negative, stage III breast cancer. Materials and methods: A quasi-experimental study was conducted from April 2022 to October 2023 in two centers in Dhaka, Bangladesh. Sixty-six patients were enrolled and divided equally into two arms. Arm-A patients received four cycles of AC followed by paclitaxel (175 mg/m2) three-weekly for four cycles. Patients in Arm-B received four cycles of AC followed by paclitaxel (80 mg/m2) weekly for 12 weeks. Patients were evaluated before, during, and after the completion of the chemotherapy to assess clinical outcomes and were assessed for the pathological response after surgical management. Observations and results: Pathological complete response (pCR) was achieved in 15 (25%) patients. Four patients (13.33%) in Arm A and 11 patients (36.66%) in Arm B had pCR. The difference was statistically significant (p 0.037). The p-value was 0.219 for response at the primary site and 0.13 for response in axillary disease. In both arms, patients with triple-negative receptor status had increased pCR (22.22% or two patients out of nine in Arm A, and 85.71% or six patients out of seven in Arm B) in comparison to hormone receptor (estrogen receptor (ER) and/or progesterone receptor (PR)) positive tumors (9.52% or two patients out of 21 in Arm A, and 21.74% or five patients out of 23 in Arm B). However, these differences were not significant. Conclusion: After three-weekly administrations of four cycles of AC, the weekly administration of paclitaxel was found to be more effective in comparison to three-weekly administration of paclitaxel.
- 25 February 2025
- Published by Springer Nature in Cureus
- Vol. 17 (2) , e79636
Open AccessWeekly Versus Three-Weekly Administration of Paclitaxel as Neoadjuvant Chemotherapy in HER2 Negative, Stage III Breast Cancer: A Comparison of Treatment Responses
Background and aim: Neoadjuvant chemotherapy with doxorubicin (A) and cyclophosphamide (C) followed by taxane (T) (AC followed by T) is one of the standard regimens in locoregionally advanced breast cancer. Paclitaxel, a taxane, can be given either in a three-weekly or a weekly schedule. The aim of this study was to compare the efficacy in terms of the clinical and pathological response of three-weekly paclitaxel with weekly paclitaxel in the treatment of human epidermal growth factor receptor 2 (HER2)-negative, stage III breast cancer. Materials and methods: A quasi-experimental study was conducted from April 2022 to October 2023 in two centers in Dhaka, Bangladesh. Sixty-six patients were enrolled and divided equally into two arms. Arm-A patients received four cycles of AC followed by paclitaxel (175 mg/m2) three-weekly for four cycles. Patients in Arm-B received four cycles of AC followed by paclitaxel (80 mg/m2) weekly for 12 weeks. Patients were evaluated before, during, and after the completion of the chemotherapy to assess clinical outcomes and were assessed for the pathological response after surgical management. Observations and results: Pathological complete response (pCR) was achieved in 15 (25%) patients. Four patients (13.33%) in Arm A and 11 patients (36.66%) in Arm B had pCR. The difference was statistically significant (p 0.037). The p-value was 0.219 for response at the primary site and 0.13 for response in axillary disease. In both arms, patients with triple-negative receptor status had increased pCR (22.22% or two patients out of nine in Arm A, and 85.71% or six patients out of seven in Arm B) in comparison to hormone receptor (estrogen receptor (ER) and/or progesterone receptor (PR)) positive tumors (9.52% or two patients out of 21 in Arm A, and 21.74% or five patients out of 23 in Arm B). However, these differences were not significant. Conclusion: After three-weekly administrations of four cycles of AC, the weekly administration of paclitaxel was found to be more effective in comparison to three-weekly administration of paclitaxel.
- Open Access
- 29 March 2024
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 12 (4) , 1097-1100
Clinico-pathological profile of breast cancer patients in a radiation therapy centre
Background: The aim of the study was to evaluate the clinico-pathological characteristics of patients with breast cancer at the Radiation Center of Bangabandhu Sheikh Mujib Medical University (BSMMU), a tertiary‑care cancer center in Dhaka, Bangladesh. Methods: This descriptive study was conducted from March 2021 to February 2022 where patients receiving radiotherapy for breast cancer were included. Data were collected from face-to-face interviews with patients and from their investigation reports. Data regarding age, presenting symptoms, histological type, tumor size, involvement of regional nodes, hormonal receptor status, and human epidermal growth factor receptor 2 (HER2) amplification were recorded and then analyzed. Results: The mean age of the patients was 52.53 years. Most of the patients (93%) were multiparous and 62.24% were postmenopausal. The most common symptom was breast lump (91.6%). Infiltrating ductal carcinoma and lobular carcinoma were seen in 136 (95.1%) and 7 (4.9%) cases respectively. The TNM stage distribution was stage I, 6 (4.2%); stage II, 52 (36.36%); stage III, 76 (53.15%); and stage IV, 9 (6.29%). Locally advanced breast cancer constituted 42.66% of the cases. Among the patients 90 (62.94%) patients were ER/PR positive and 42 (29.37%) patients were HER2 positive. Triple negative breast cancer (TNBC) constituted 25.17% (36) of the study population. All receptors were positive in 25 patients (17.48%). Conclusions: Majority of our patients receiving breast radiotherapy at our center are middle aged and have advanced disease. TNBC and HER2 positive breast cancer are more common in our population.
- 29 March 2024
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 12 (4) , 1097-1100
Open AccessClinico-pathological profile of breast cancer patients in a radiation therapy centre
Background: The aim of the study was to evaluate the clinico-pathological characteristics of patients with breast cancer at the Radiation Center of Bangabandhu Sheikh Mujib Medical University (BSMMU), a tertiary‑care cancer center in Dhaka, Bangladesh. Methods: This descriptive study was conducted from March 2021 to February 2022 where patients receiving radiotherapy for breast cancer were included. Data were collected from face-to-face interviews with patients and from their investigation reports. Data regarding age, presenting symptoms, histological type, tumor size, involvement of regional nodes, hormonal receptor status, and human epidermal growth factor receptor 2 (HER2) amplification were recorded and then analyzed. Results: The mean age of the patients was 52.53 years. Most of the patients (93%) were multiparous and 62.24% were postmenopausal. The most common symptom was breast lump (91.6%). Infiltrating ductal carcinoma and lobular carcinoma were seen in 136 (95.1%) and 7 (4.9%) cases respectively. The TNM stage distribution was stage I, 6 (4.2%); stage II, 52 (36.36%); stage III, 76 (53.15%); and stage IV, 9 (6.29%). Locally advanced breast cancer constituted 42.66% of the cases. Among the patients 90 (62.94%) patients were ER/PR positive and 42 (29.37%) patients were HER2 positive. Triple negative breast cancer (TNBC) constituted 25.17% (36) of the study population. All receptors were positive in 25 patients (17.48%). Conclusions: Majority of our patients receiving breast radiotherapy at our center are middle aged and have advanced disease. TNBC and HER2 positive breast cancer are more common in our population.
- Open Access
- 4 December 2023
- Published by Medip Academy in International Journal of Advances in Medicine
- Vol. 11 (1) , 1-6
Knowledge, attitude and practice regarding enteric fever among doctors of Bangabandhu Sheikh Mujib Medical University
Background: Enteric fever remains a significant public health challenge, particularly in developing countries. Understanding the knowledge, attitudes, and practices of general practitioners regarding enteric fever is crucial for effective disease management and control. This study aims to assess these aspects among general practitioners, providing insights into current practices and identifying areas for improvement. Methods: This cross-sectional survey was conducted with 200 general practitioners. The questionnaire covered various aspects, including baseline characteristics, knowledge about enteric fever causative agents and symptoms, diagnostic practices, antibiotic preferences, and general attitudes towards management and prevention. Data were analyzed to determine the prevalence of specific knowledge and practices. Results: Majority of practitioners (74%) were residents, predominantly working indoors (61.5%). All respondents correctly identified Salmonella typhi and para typhi as causative agents and fever as a primary symptom. However, there was variability in recognizing other symptoms and diagnostic methods. Ceftriaxon was the most preferred antibiotic (67%), and blood culture correctly identified as gold standard for diagnosis by 71% of respondents. Attitudes and practices varied, with significant number not adhering to recommended diagnostic and treatment protocols. Conclusions: The study reveals a solid foundation of basic knowledge about enteric fever among general practitioners but also highlights significant gaps in the understanding of clinical symptoms, diagnostic practices, and treatment protocols. These findings underscore the need for enhanced educational initiatives and standardized guidelines to improve the management of enteric fever.
- 4 December 2023
- Published by Medip Academy in International Journal of Advances in Medicine
- Vol. 11 (1) , 1-6
Open AccessKnowledge, attitude and practice regarding enteric fever among doctors of Bangabandhu Sheikh Mujib Medical University
Background: Enteric fever remains a significant public health challenge, particularly in developing countries. Understanding the knowledge, attitudes, and practices of general practitioners regarding enteric fever is crucial for effective disease management and control. This study aims to assess these aspects among general practitioners, providing insights into current practices and identifying areas for improvement. Methods: This cross-sectional survey was conducted with 200 general practitioners. The questionnaire covered various aspects, including baseline characteristics, knowledge about enteric fever causative agents and symptoms, diagnostic practices, antibiotic preferences, and general attitudes towards management and prevention. Data were analyzed to determine the prevalence of specific knowledge and practices. Results: Majority of practitioners (74%) were residents, predominantly working indoors (61.5%). All respondents correctly identified Salmonella typhi and para typhi as causative agents and fever as a primary symptom. However, there was variability in recognizing other symptoms and diagnostic methods. Ceftriaxon was the most preferred antibiotic (67%), and blood culture correctly identified as gold standard for diagnosis by 71% of respondents. Attitudes and practices varied, with significant number not adhering to recommended diagnostic and treatment protocols. Conclusions: The study reveals a solid foundation of basic knowledge about enteric fever among general practitioners but also highlights significant gaps in the understanding of clinical symptoms, diagnostic practices, and treatment protocols. These findings underscore the need for enhanced educational initiatives and standardized guidelines to improve the management of enteric fever.
- 11 April 2023
- Published by SASPR Edu International Pvt. Ltd in SAS Journal of Medicine
- Vol. 9 (04) , 277-282
Clinico-Epidemiological Features with Gastric Cancer Patients Presenting at Bangabandhu Sheikh Mujib Medical University, Bangladesh
Background: Gastric carcinoma is one of the commonest cancers in Bangladesh. The goal of this study was to assess at the clinico-epidemiological characteristics of individuals with gastric cancer. Methods: This descriptive, cross- sectional study was conducted from November 2021 to October 2022, 120 patients with gastric cancer were included at Bangabandhu Sheikh Mujib Medical University (BSMMU), Department of Clinical Oncology. A pre-made questionnaire was used to collect data from patients during face-to-face interviews. Results: The mean age of the patients was 53.0 (±11.496) years, most of the patients (46.6%) were 51 – 60 years of age, 75.0 % of enrolled patients were male, 35.0 % of patients were service holder. The bulk of the cases had H. pylori infection (73.3%). The most common histological type among the patients was adenocarcinoma (95%). In terms of primary tumor location, the gastric antrum (50.0%) was the most prevalent subsite. Most of the patients were diagnosed as locally advanced stage. Conclusions: In conclusion, gastric cancer occurs mainly in middle aged males and associated with H. pylori infection. Adenocarcinoma is the most frequent histological form, with the gastric antrum as the main location of tumors and advanced stage.
- 11 April 2023
- Published by SASPR Edu International Pvt. Ltd in SAS Journal of Medicine
- Vol. 9 (04) , 277-282
Clinico-Epidemiological Features with Gastric Cancer Patients Presenting at Bangabandhu Sheikh Mujib Medical University, Bangladesh
Background: Gastric carcinoma is one of the commonest cancers in Bangladesh. The goal of this study was to assess at the clinico-epidemiological characteristics of individuals with gastric cancer. Methods: This descriptive, cross- sectional study was conducted from November 2021 to October 2022, 120 patients with gastric cancer were included at Bangabandhu Sheikh Mujib Medical University (BSMMU), Department of Clinical Oncology. A pre-made questionnaire was used to collect data from patients during face-to-face interviews. Results: The mean age of the patients was 53.0 (±11.496) years, most of the patients (46.6%) were 51 – 60 years of age, 75.0 % of enrolled patients were male, 35.0 % of patients were service holder. The bulk of the cases had H. pylori infection (73.3%). The most common histological type among the patients was adenocarcinoma (95%). In terms of primary tumor location, the gastric antrum (50.0%) was the most prevalent subsite. Most of the patients were diagnosed as locally advanced stage. Conclusions: In conclusion, gastric cancer occurs mainly in middle aged males and associated with H. pylori infection. Adenocarcinoma is the most frequent histological form, with the gastric antrum as the main location of tumors and advanced stage.
- Open Access
- 11 April 2023
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 11 (5) , 1435-1438
Clinico-epidemiological features of hypopharyngeal cancer patients presenting at Bangabandhu Sheikh Mujib medical university, Bangladesh
Background: In Bangladesh, hypopharyngeal cancer is one of the most prevalent cancers in head neck region. In this study, the clinico-epidemiological characteristics of patients with hypopharyngeal cancer were evaluated. Methods: From November 2021 to October 2022, 172 patients with hypopharyngeal carcinoma were included in this descriptive, cross-sectional study at Bangabandhu Sheikh Mujib medical university's department of clinical oncology. During in-person interviews, data were gathered from patients using a pre-made questionnaire. Results: The mean age of the patients was 54.42 (±7.652) years, and the majority of them (59.3%) were between the ages of 51 and 60. Male patients made up 81.4% of the total patient population, and 51.16% of them were farmers. The majority of the cases (79.07%) consumed tobacco. Squamous cell carcinoma was the most prevalent histological type among the patients (92%), and most of them had a moderate degree of differentiation (65.12%). The pyriform fossa (81.4%) was the most common primary sub site. Conclusions: In conclusion, tobacco users and middle-aged men are more likely to develop hypopharyngeal cancer. The most common histological type is moderately differentiated squamous cell carcinoma, with tumours most commonly seen in the pyriform fossa of hypopharynx.
- 11 April 2023
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 11 (5) , 1435-1438
Open AccessClinico-epidemiological features of hypopharyngeal cancer patients presenting at Bangabandhu Sheikh Mujib medical university, Bangladesh
Background: In Bangladesh, hypopharyngeal cancer is one of the most prevalent cancers in head neck region. In this study, the clinico-epidemiological characteristics of patients with hypopharyngeal cancer were evaluated. Methods: From November 2021 to October 2022, 172 patients with hypopharyngeal carcinoma were included in this descriptive, cross-sectional study at Bangabandhu Sheikh Mujib medical university's department of clinical oncology. During in-person interviews, data were gathered from patients using a pre-made questionnaire. Results: The mean age of the patients was 54.42 (±7.652) years, and the majority of them (59.3%) were between the ages of 51 and 60. Male patients made up 81.4% of the total patient population, and 51.16% of them were farmers. The majority of the cases (79.07%) consumed tobacco. Squamous cell carcinoma was the most prevalent histological type among the patients (92%), and most of them had a moderate degree of differentiation (65.12%). The pyriform fossa (81.4%) was the most common primary sub site. Conclusions: In conclusion, tobacco users and middle-aged men are more likely to develop hypopharyngeal cancer. The most common histological type is moderately differentiated squamous cell carcinoma, with tumours most commonly seen in the pyriform fossa of hypopharynx.
- Open Access
- 7 February 2023
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 11 (3) , 758-762
Post treatment outcome and quality of life in patients with inoperable advanced gastric carcinoma
Background: The outcome of treatment for advanced gastric carcinoma can vary depending on a number of factors, including the stage and aggressiveness of the cancer, the patient's overall health, and their response to treatment. In general, the prognosis is poor, with a median overall survival of less than one year. Quality of life (QOL) is an important consideration for patients with advanced gastric carcinoma, as they may experience a range of symptoms such as pain, fatigue, and difficulty eating. This study aimed to evaluate the post-treatment outcomes and QOL in patients with inoperable advanced gastric carcinoma after treatment with cisplatin-capecitabine and with oxaliplatin-capecitabine. Methods: This Quasi-experimental study was conducted at the department of oncology, Bangabandhu Sheikh Mujib medical university, Dhaka, Bangladesh. The study duration was 1 year, from February 2021 to March 2022. During this period, a total of 64 cases of advanced gastric cancer were divided in two equal groups, arm A who had received cisplatin capecitabine, and arm B who received oxaliplatin capecitabine. Result: The mean age at diagnosis was 55.85 and 56.76 respectively. The majority of the patients, 43.8% in arm A and 50% in arm B, ranged in age from 61 to 70. The gender distribution was similar, 78% and 69% of patients in arm A and B respectively were male. Both groups had the majority of patients receiving an ECOG performance rating of 2, with 68.8% in arm A and 59.4% in arm B, and the liver being the most common metastatic site for 56.3% in arm A and 50.0% in arm B. The most frequent risk factor was Helicobacter pylori infection, observed in 68.8% of arm A and 78.1% of arm B. The most common primary tumor site was the antrum, with 50% and 53.1% patients in arm A and B respectively had the primary tumor in the antrum of the stomach. Conclusions: In inoperable advanced gastric cancer, the cisplatin-capecitabine regimen is equally effective as oxaliplatin-capecitabine in terms of disease outcome. Furthermore, the cisplatin-capecitabine regimen is less costly than the combination of oxaliplatin-capecitabine, and provides almost similar QOL. As a result, the cisplatin-capecitabine regimen could be utilized as an alternate choice in patients who are unable to afford an oxaliplatin-based regimen.
- 7 February 2023
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 11 (3) , 758-762
Open AccessPost treatment outcome and quality of life in patients with inoperable advanced gastric carcinoma
Background: The outcome of treatment for advanced gastric carcinoma can vary depending on a number of factors, including the stage and aggressiveness of the cancer, the patient's overall health, and their response to treatment. In general, the prognosis is poor, with a median overall survival of less than one year. Quality of life (QOL) is an important consideration for patients with advanced gastric carcinoma, as they may experience a range of symptoms such as pain, fatigue, and difficulty eating. This study aimed to evaluate the post-treatment outcomes and QOL in patients with inoperable advanced gastric carcinoma after treatment with cisplatin-capecitabine and with oxaliplatin-capecitabine. Methods: This Quasi-experimental study was conducted at the department of oncology, Bangabandhu Sheikh Mujib medical university, Dhaka, Bangladesh. The study duration was 1 year, from February 2021 to March 2022. During this period, a total of 64 cases of advanced gastric cancer were divided in two equal groups, arm A who had received cisplatin capecitabine, and arm B who received oxaliplatin capecitabine. Result: The mean age at diagnosis was 55.85 and 56.76 respectively. The majority of the patients, 43.8% in arm A and 50% in arm B, ranged in age from 61 to 70. The gender distribution was similar, 78% and 69% of patients in arm A and B respectively were male. Both groups had the majority of patients receiving an ECOG performance rating of 2, with 68.8% in arm A and 59.4% in arm B, and the liver being the most common metastatic site for 56.3% in arm A and 50.0% in arm B. The most frequent risk factor was Helicobacter pylori infection, observed in 68.8% of arm A and 78.1% of arm B. The most common primary tumor site was the antrum, with 50% and 53.1% patients in arm A and B respectively had the primary tumor in the antrum of the stomach. Conclusions: In inoperable advanced gastric cancer, the cisplatin-capecitabine regimen is equally effective as oxaliplatin-capecitabine in terms of disease outcome. Furthermore, the cisplatin-capecitabine regimen is less costly than the combination of oxaliplatin-capecitabine, and provides almost similar QOL. As a result, the cisplatin-capecitabine regimen could be utilized as an alternate choice in patients who are unable to afford an oxaliplatin-based regimen.
- 30 January 2023
- Published by Valley International in Journal of Medical Science And clinical Research
- Vol. 11 (01) , 97-104
Low dose weekly Carboplatin (AUC: 2) with radiation is an acceptable alternative for weekly cisplatin with radiation in the treatment of advanced head neck carcinoma: An observational study
Introduction: In general head and neck cancer may be treated with single modality of treatment for early-stage disease but may require multimodality treatment protocol for advanced disease. concurrent chemoradiation is the current standard protocol for patients with locally advanced squamous cell carcinoma of head neck. Carcinoma of head and neck is common clinical entity approximately 4.8% of the total new-cancer cases. In Bangladesh, according to cancer Registry Report NICRH (20015-2017), approximately 2901(10.6%) patients ire registered with head and neck cancer. Study Design and Objective: This prospective observational study is to compare the treatment response and acute toxicities with the treatment of low dose weekly Carboplatin(AUC:2) with radiation versus weekly Cisplatin with radiation therapy for histologically proven advanced squamous cell carcinoma of head neck. Methods: All the patients were divided in two groups. Arm-A 30 number patients received injection Carboplatin (AUC:2), i/v 30 minutes infusion weekly for 6 weeks and Arm-B 30 number patients received injection Cisplatin 30mg/m 2 , i/v 2 hrs. infusion weekly for 6 weeks. All patients received 66 Gray (Gy) radiation at the rate of 2Gy/day 5# in a week for 6.5 weeks. Results: In this study ninety percent (90%) patients were smoker. The most common presenting features were cervical lymphadenopathy (Arm A 100% vs. Arm B 100%), pain (Arm A 73.33% vs. Arm B 66.67%), sore throat (Arm A 36.67% vs. Arm B 36.66%), hoarseness of voice (Arm A 36.67% vs. Arm B 36.66%) etc. Complete response of patients treated with concurrent chemoradiation with inj. Carboplatin was 63.33% in comparison to 53.33% complete response achieved in patients treated with concurrent chemoradiation with inj. Cisplatin. This difference was statistically not much more significant. Common toxicities related to treatment were mucositis, skin reaction, vomiting, nausea, weight loss, anemia, leucopenia, thrombocytopenia and diarrhea. The toxicities in Arm-A were more than that of Arm-B, but were manageable. Conclusion: In this study the clinical response and toxicities produced by weekly low dose carboplatin with radiation in locally advanced squamous cell carcinoma of head and neck cancer were comparable to those of weekly Cisplatin schedule with radiation showed no additional efficacy. So, concurrent chemoradiotherapy with weekly Carboplatin (AUC:2) is suitable when Cisplatin is contraindicated for the patients with renal impairment.
- 30 January 2023
- Published by Valley International in Journal of Medical Science And clinical Research
- Vol. 11 (01) , 97-104
Low dose weekly Carboplatin (AUC: 2) with radiation is an acceptable alternative for weekly cisplatin with radiation in the treatment of advanced head neck carcinoma: An observational study
Introduction: In general head and neck cancer may be treated with single modality of treatment for early-stage disease but may require multimodality treatment protocol for advanced disease. concurrent chemoradiation is the current standard protocol for patients with locally advanced squamous cell carcinoma of head neck. Carcinoma of head and neck is common clinical entity approximately 4.8% of the total new-cancer cases. In Bangladesh, according to cancer Registry Report NICRH (20015-2017), approximately 2901(10.6%) patients ire registered with head and neck cancer. Study Design and Objective: This prospective observational study is to compare the treatment response and acute toxicities with the treatment of low dose weekly Carboplatin(AUC:2) with radiation versus weekly Cisplatin with radiation therapy for histologically proven advanced squamous cell carcinoma of head neck. Methods: All the patients were divided in two groups. Arm-A 30 number patients received injection Carboplatin (AUC:2), i/v 30 minutes infusion weekly for 6 weeks and Arm-B 30 number patients received injection Cisplatin 30mg/m 2 , i/v 2 hrs. infusion weekly for 6 weeks. All patients received 66 Gray (Gy) radiation at the rate of 2Gy/day 5# in a week for 6.5 weeks. Results: In this study ninety percent (90%) patients were smoker. The most common presenting features were cervical lymphadenopathy (Arm A 100% vs. Arm B 100%), pain (Arm A 73.33% vs. Arm B 66.67%), sore throat (Arm A 36.67% vs. Arm B 36.66%), hoarseness of voice (Arm A 36.67% vs. Arm B 36.66%) etc. Complete response of patients treated with concurrent chemoradiation with inj. Carboplatin was 63.33% in comparison to 53.33% complete response achieved in patients treated with concurrent chemoradiation with inj. Cisplatin. This difference was statistically not much more significant. Common toxicities related to treatment were mucositis, skin reaction, vomiting, nausea, weight loss, anemia, leucopenia, thrombocytopenia and diarrhea. The toxicities in Arm-A were more than that of Arm-B, but were manageable. Conclusion: In this study the clinical response and toxicities produced by weekly low dose carboplatin with radiation in locally advanced squamous cell carcinoma of head and neck cancer were comparable to those of weekly Cisplatin schedule with radiation showed no additional efficacy. So, concurrent chemoradiotherapy with weekly Carboplatin (AUC:2) is suitable when Cisplatin is contraindicated for the patients with renal impairment.